Vifor Pharma enhances its portfolio by acquiring Inositec. The advisors
Vifor Pharma acquires the Swiss firm Inositec, a clinical stage biopharmaceutical company which is developing first-in-class treatments for unmet medical need. Through this acquisitions, Vifor Pharma will be spearheading the vascular calcification field to improve lives of more than 600,000 patients in U.S. and EU suffering from peripheral artery disease.
Subject to the closing,that could take place in the fourth quarter of 2021, the shareholders of Inositec will receive a fixed consideration of CHF 20 million and possible milestone payments in the low three-digit million range.
The advisors
Kellerhals Carrard provided comprehensive legal advice to Vifor Pharma on its acquisition of Inositec. The team was led by managing partner Beat Brechbühl (pictured) and included senior associate Nicolai Nuber and associate Shayan Mirabi.
Vischer advised its longtime client, Inositec. The team was led by Matthias Staehelin (partner, pictured left) with Pauline Pfirter (associate), Sebastian Flückiger (senior associate) and Luzius Zumstein (senior associate), all corporate.
Vifor Pharma has also acquired the Spanish company Sanifit Therapeutics. Vifor Pharma will completely take over the outstanding shares of Sanifit Therapeutics. The shareholders of Sanifit received an advance payment of € 205 million, clinical, regulatory and market-related milestones of up to 170 million as well as staggered sales-dependent milestones that could reach a mid to high three-digit million amount with peak sales.
